Advances in Analytical Techniques for Personalized Medicine

Divya Narla

Associate Professor,

Department of Pharmaceutical Analysis

Aditya College of Pharmacy

Surampalem, India

divyanarla@gmail.com

Prakash Nathaniel Kumar Sarella

Associate Professor, Department of Pharmaceutics

Aditya College of Pharmacy

Surampalem, India

sarellaprakash@acop.edu.in

ABSTRACT

The chapter "Advances in Analytical Techniques for Personalized Medicine" explores the transformative role of analytical methods in tailoring medical treatments to individual patients. Personalized medicine, a paradigm shift in healthcare, is driven by the understanding that each patient's genetic makeup, molecular profile, and lifestyle factors influence treatment responses. Genomic and proteomic analyses enable identification of biomarkers that guide treatment stratification, optimizing therapeutic outcomes. Pharmacogenomics utilizes genetic variations to predict drug metabolism, enabling precise drug selection and dosage adjustment. The interplay between patients' microbiomes and treatment responses is uncovered through advanced microbiome analysis, contributing to personalized therapies. Metabolomics provides diagnostic insights by profiling metabolic signatures associated with diseases and treatment efficacy. Cutting-edge imaging techniques allow non-invasive tracking of disease progression and response to therapies. Point-of-care diagnostics and wearable sensors empower real-time patient monitoring, enhancing personalized care. Bioinformatics and data integration facilitate meaningful interpretation of multi-omics data, aiding clinical decision-making. The chapter also addresses ethical considerations surrounding patient data privacy and regulatory challenges. Case studies underscore successful applications of analytical techniques in personalized cancer therapies and rare disease treatments. In a rapidly advancing landscape, this chapter outlines the potential and challenges of integrating analytical innovations into personalized medicine, revolutionizing patient-centered healthcare.

Keywords— Personalized medicine; Analytical techniques; Genomics; Pharmacogenomics; Metabolomics; imaging; Point-of-care diagnostics.

# INTRODUCTION

Personalized medicine represents a groundbreaking approach in healthcare that tailors medical interventions to the unique characteristics of each individual patient. Unlike the traditional one-size-fits-all model, personalized medicine takes into account a patient's genetic makeup, molecular profile, lifestyle, and environmental factors to determine the most effective treatment strategies. This approach recognizes that individuals respond differently to medications and therapies due to their inherent genetic variability [1], [2].

The fundamental principle of personalized medicine is to optimize treatment outcomes by identifying the most suitable interventions based on a patient's genetic predisposition and specific health conditions. Advances in analytical techniques have played a pivotal role in enabling personalized medicine to become a reality. High-throughput genomic sequencing, proteomic analysis, and metabolomic profiling have opened new avenues for understanding the intricate molecular underpinnings of diseases and treatment responses[3], [4].

This chapter delves into the core concepts of personalized medicine and how cutting-edge analytical techniques are driving its implementation. It explores how genetic and molecular insights are guiding treatment decisions, emphasizing the shift from a reactive treatment approach to a proactive and preventive one. Through a comprehensive exploration of the analytical tools and strategies that underpin personalized medicine, this chapter sets the stage for the subsequent discussions on the specific advances in analytical techniques that are shaping the future of healthcare in the context of personalized medicine.

# GENOMIC AND PROTEOMIC ANALYSIS

Genomic and proteomic analyses form the bedrock of personalized medicine, unraveling the intricate genetic and molecular signatures that define an individual's health profile[5]. These advanced analytical techniques enable healthcare professionals to gain unprecedented insights into the underlying mechanisms of diseases and tailor treatments accordingly

## **Genomic Analysis: Decoding Genetic Blueprint**

Genomic analysis involves sequencing an individual's DNA to identify variations, mutations, and genetic markers that can influence disease susceptibility, drug metabolism, and treatment response. By understanding these genetic factors, clinicians can predict a patient's predisposition to certain diseases and select the most effective therapies. Pharmacogenomics, a subfield of genomic analysis, focuses on how an individual's genetic makeup impacts their response to medications. This knowledge allows healthcare providers to choose medications and dosages that are most likely to be safe and efficacious[6].

## **Proteomic Analysis: Unveiling Molecular Signatures**

Proteomics involves the systematic study of an individual's proteins, which are the functional workhorses of the body. Proteomic analysis can identify specific proteins that are overexpressed, underexpressed, or post-translationally modified in various diseases. These molecular fingerprints provide crucial information about disease progression and potential therapeutic targets. In personalized medicine, proteomics guides treatment decisions by pinpointing unique molecular markers that can indicate the efficacy of targeted therapies[7].

The integration of genomic and proteomic analyses empowers healthcare professionals to develop highly individualized treatment strategies. By harnessing the power of these analytical techniques, personalized medicine transforms healthcare from a reactive approach to a proactive one, enabling more precise and effective interventions tailored to each patient's unique genetic and molecular characteristics[8].

# PHARMACOGENOMICS AND DRUG OPTIMIZATION

Pharmacogenomics, an integral component of personalized medicine, embodies the convergence of genetics and pharmacology. It seeks to decipher the genetic factors influencing an individual's response to medications, paving the way for optimized drug selection, dosing, and therapeutic outcomes [9].

## **Understanding Genetic Variability**

At the heart of pharmacogenomics lies the understanding that genetic variations among individuals can significantly impact how drugs are metabolized and their efficacy. These genetic polymorphisms can affect drug absorption, distribution, metabolism, and excretion, collectively shaping an individual's drug response and susceptibility to adverse reactions. By identifying these genetic variations, healthcare providers can predict a patient's likelihood of responding positively or negatively to specific drugs[10]. The examples of pharmacogenomic variations and drug responses are shown in Table 1.

**Table 1: Examples of Pharmacogenomic Variations and Drug Responses**

|  |  |  |  |
| --- | --- | --- | --- |
| **Gene** | **Variation** | **Drug** | **Response** |
| CYP2D6 | Poor metabolizer | Codeine | Ineffective pain relief |
| Tramadol | Reduced pain relief |
| TPMT | Intermediate TPMT | Thiopurine drugs | Increased toxicity risk |
| Mercaptopurine | Enhanced myelosuppression |
| VKORC1 | High sensitivity | Warfarin | Increased bleeding risk |
| Acenocoumarol | Higher potential for bleeding |
| SLCO1B1 | \*5/\*5 genotype | Statins | Increased muscle toxicity |
| Simvastatin | Elevated risk of muscle-related effects |
| Atorvastatin | Greater likelihood of muscle issues |
| Pravastatin | Minimal muscle-related risks |

## **Tailoring Treatment for Maximum Benefit**

Pharmacogenomics guides the selection of medications and dosage adjustments to align with a patient's genetic makeup, minimizing the risk of adverse effects and treatment failures. For instance, an individual's genetic profile may indicate a slower metabolism of a certain drug, necessitating a lower dosage to prevent toxicity. Conversely, a fast metabolizer might require a higher dose to achieve therapeutic levels [11].

## **Trial and Error to Precision Medicine**

The traditional approach to prescribing medications often involved a trial-and-error process, where patients had to endure potential side effects or inadequate responses before finding an effective treatment. Pharmacogenomics revolutionizes this paradigm by allowing clinicians to preemptively tailor treatments based on genetic information, enhancing patient safety and treatment efficacy [12].

While the promise of pharmacogenomics is undeniable, its widespread integration into clinical practice presents challenges. Establishing standardized guidelines, interpreting complex genetic data, and addressing ethical considerations related to patient privacy are key areas of concern[13], [14].

# MICROBIOME AND TREATMENT RESPONSE

The human microbiome, a complex ecosystem of microorganisms inhabiting our body, has emerged as a critical player in health and disease. Recent advancements in analytical techniques have unveiled the profound impact of the microbiome on treatment responses, ushering in a new era of personalized medicine that considers our microbial inhabitants[14], [15].

## **Microbiome’s Role in Health and Disease**

The microbiome, consisting of bacteria, viruses, fungi, and other microorganisms, exerts a far-reaching influence on diverse physiological processes. It contributes to digestion, metabolism, immune modulation, and even neurological functions. Imbalances in the microbiome, known as dysbiosis, have been implicated in various diseases, ranging from gastrointestinal disorders to autoimmune conditions and beyond [16]. The microbiome modulation versus disease treatment is shown in Table 2.

**Table 2: Microbiome Modulation and Disease Treatment**

|  |  |  |  |
| --- | --- | --- | --- |
| **Disease/Condition** | **Microbiome Imbalance** | **Intervention** | **Treatment Outcome** |
| Clostridium difficile infection | Dysbiosis due to antibiotic use | Fecal Microbiota Transplantation (FMT) | Rapid resolution of infection |
| Probiotics | Improved gut flora balance, reduced recurrence |
| Inflammatory Bowel Disease | Dysbiosis in gut microbiota | Prebiotics | Reduced inflammation, enhanced gut barrier function |
| Probiotics | Symptom relief, disease management |
| Faecal Microbiota Transplantation (FMT) | Alleviation of symptoms, improved gut health |
| Obesity | Reduced microbial diversity | Dietary changes | Improved metabolic health, weight management |
| Altered gut microbiota | Exercise and dietary modifications | Enhanced weight loss, metabolic improvement |
| Prebiotics | Positive effects on gut health and weight |
| Bariatric surgery | Microbiome changes contributing to weight loss |
| Type 2 Diabetes | Dysbiosis and altered metabolic activity | High-fiber diet | Improved glucose control, metabolic benefits |
| Fecal Microbiota Transplantation (FMT) | Potential positive impact on insulin sensitivity |
| Probiotics and synbiotics | Potential modulation of gut microbiota for health |

## **Microbiome and Drug Metabolism**

Emerging evidence suggests that the microbiome can significantly affect the metabolism of drugs within the body. Certain microorganisms possess enzymes that can modify drug compounds, impacting their efficacy and toxicity. Moreover, the composition of the microbiome may influence how drugs are absorbed and distributed, influencing treatment outcomes[17].

## **Microbial Biomarkers for Treatment Response**

Analyzing the composition of a patient's microbiome could provide predictive insights into how they might respond to specific treatments. The presence or absence of certain microbial species can indicate the likelihood of treatment success or failure. In this context, the microbiome acts as a unique biomarker reservoir that can guide treatment decisions[18]. The role of biomarkers in disease diagnosis is listed out in Table 3.

**Table 3: Biomarker Discovery and Disease Diagnosis**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Biomarker** | **Disease/Condition** | **Analytical Technique** | **Diagnostic Application** | **Potential Treatment Strategy** |
| KRAS mutation | Colorectal cancer | Next-generation sequencing (NGS) | Mutation detection for early diagnosis | Targeted therapy with specific inhibitors |
| BCR-ABL fusion | Chronic myeloid leukemia | Polymerase chain reaction (PCR) | Confirming diagnosis, disease monitoring | Tyrosine kinase inhibitors |
| HER2 expression | Breast cancer | Immunohistochemistry (IHC) | Stratification for targeted therapy | HER2-targeted therapies |
| PSA levels | Prostate cancer | Enzyme-linked immunosorbent assay (ELISA) | Screening and disease monitoring | Active surveillance or treatment |
| Troponin levels | Acute myocardial infarction | Cardiac troponin assay | Early detection of heart damage | Cardiac interventions and therapies |
| Aβ42/Aβ40 ratio | Alzheimer's disease | Immunoassays and mass spectrometry | Early detection and risk assessment | Disease-modifying therapies |
| BNP levels | Heart failure | B-type natriuretic peptide (BNP) assay | Diagnosis and disease severity assessment | Medication and lifestyle management |
| PGRN mutations | Frontotemporal dementia | Genetic sequencing | Genetic confirmation and risk assessment | Symptomatic and supportive care |

## **Personalized Therapies via Microbiome Modulation**

Emerging evidence suggests that the microbiome can significantly affect the metabolism of drugs within the body. Certain microorganisms possess enzymes that can modify drug compounds, impacting their efficacy and toxicity. Moreover, the composition of the microbiome may influence how drugs are absorbed and distributed, influencing treatment outcomes[19]–[21].

# IMAGING FOR PERSONALIZED CARE

## **Molecular Imaging for Precise Diagnosis**

Molecular imaging techniques enable healthcare professionals to visualize specific molecules and biological processes within the body. Positron emission tomography (PET), single-photon emission computed tomography (SPECT), and magnetic resonance imaging (MRI) with specialized contrast agents allow the detection of molecular markers associated with diseases. This high level of precision aids in early diagnosis and accurate disease staging[22].

## **Theranostics: Integrating Imaging and Therapy**

The concept of "theranostics" involves combining diagnostic and therapeutic capabilities into a single platform. Molecular imaging techniques can be paired with targeted therapies, enabling healthcare providers to monitor treatment response in real time. This dynamic feedback loop empowers clinicians to adjust treatments based on individual patient's responses, optimizing outcomes[23].

## **Non-Invasive Monitoring of Treatment Response**

Imaging techniques such as functional MRI (fMRI) and diffusion-weighted imaging (DWI) offer non-invasive methods to monitor changes in tissue structure and function over time. These tools enable clinicians to assess how tumors and other conditions are responding to treatment, allowing for timely adjustments if necessary[24].

## **Imaging-guided interventions**

Personalized medicine extends to interventional procedures, where imaging technologies guide minimally invasive surgeries and treatments. Real-time imaging feedback ensures precision and accuracy during procedures, minimizing damage to healthy tissue and improving patient outcomes[24].

# POINT OF CARE DIAGNOSTICS

Point-of-care diagnostics is at the forefront of transforming healthcare delivery by bringing advanced analytical capabilities directly to the patient's bedside. This approach eliminates the need for time-consuming laboratory testing, enabling rapid and informed clinical decisions that are essential for personalized care[25].

## **Instantaneous Testing for Immediate Action**

Point-of-care diagnostics involve portable and user-friendly devices that provide quick and accurate results, often within minutes. These devices enable healthcare professionals to make timely decisions, whether it's adjusting treatment regimens, initiating interventions, or making critical triage choices[26].

## **Wearable Sensors for Continuous Monitoring**

The integration of wearable sensors further extends point-of-care diagnostics beyond the clinical setting. These devices continuously collect data on vital signs, biomarkers, and other health indicators. The real-time data generated by wearables empowers patients to actively participate in managing their health and allows healthcare providers to tailor treatments based on constantly updated information[27].

## **Remote monitoring for personalized interventions**

In addition to real-time monitoring, point-of-care diagnostics allow for remote monitoring, especially valuable for patients in rural or underserved areas. Telemedicine coupled with point-of-care devices enables healthcare providers to remotely assess patients' conditions and recommend appropriate interventions, bridging geographical gaps in access to specialized care[28].

## **Enhancing early detection and prevention**

The rapid results from point-of-care tests aid in the early detection of diseases, facilitating prompt interventions that can significantly impact patient outcomes. From identifying infectious diseases to managing chronic conditions, these diagnostics empower healthcare providers to intervene early and effectively[29], [30].

# BIOINFORMATICS AND DATA INTEGRATION


Bioinformatics and data integration play a pivotal role in translating the vast amount of complex biological data generated by modern analytical techniques into actionable insights for personalized medicine. These fields provide the tools and strategies needed to extract meaningful information from diverse datasets, enabling healthcare professionals to make informed decisions tailored to individual patients[31].

## **Managing the data deluge**

The advent of high-throughput technologies like genomics, proteomics, and metabolomics has resulted in an explosion of biological data. Bioinformatics involves developing computational tools and algorithms to process, analyze, and interpret these large datasets. It transforms raw data into comprehensible information, revealing patterns, correlations, and potential biomarkers[32].

## **Integrating multi-omics data**

In personalized medicine, a holistic view of a patient's health profile often requires the integration of data from multiple omics disciplines, such as genomics, proteomics, and metabolomics. Data integration tools allow for the correlation of genetic variations, molecular expression patterns, and metabolic signatures, providing a more comprehensive understanding of disease mechanisms and treatment responses[33]. The integration of multi-omics data in personalized medicine is illustrated in Figure 1.



**Figure 1: Data Integration in Personalized Medicine**

## **Predictive modeling for treatment responses**

Bioinformatics enables the development of predictive models that use patient-specific data to forecast treatment outcomes. By identifying patterns in large datasets, these models can help healthcare providers anticipate how a patient might respond to a particular therapy, facilitating treatment decisions that are more likely to succeed[34].

## **Enabling precision medicine approaches**

Data integration is essential for applying precision medicine approaches, where treatment decisions are tailored to a patient's unique characteristics. Integrating clinical data, genetic information, biomarker profiles, and other relevant data points allows for a holistic view of the patient, enabling healthcare providers to design personalized treatment strategies[35].

# ETHICAL CONSIDERATIONS

As personalized medicine continues to evolve, it brings forth a host of ethical considerations that warrant careful reflection. The integration of advanced analytical techniques into healthcare raises questions about patient privacy, data security, consent, and the equitable distribution of benefits. Addressing these ethical concerns is crucial to ensuring that the promise of personalized medicine is realized while safeguarding patient rights and societal values[36].

## **Patient Data Privacy and Security**

The use of sensitive patient data, including genetic information and health records, necessitates robust privacy measures. Safeguarding this data against breaches and unauthorized access is paramount. Striking a balance between data sharing for research purposes and protecting patient identities is a delicate ethical challenge[37].

## **Informed Consent in the Genomic Era**

In personalized medicine, the scope of information gathered goes beyond traditional medical history. Patients must be adequately informed about the implications of sharing their genetic and molecular data. Informed consent must be comprehensive and clear, ensuring that individuals understand the potential risks and benefits of participating in personalized medicine initiatives[38].

## **Equity and Accessibility**

As personalized medicine advances, there's a risk of creating health disparities if access to cutting-edge treatments and diagnostics is unevenly distributed. Ensuring equitable access for all segments of the population, regardless of socioeconomic status or geographic location, is an ethical imperative[38].

## **Data Ownership and Sharing**

Deciding who owns the data generated through personalized medicine initiatives is a complex ethical dilemma. Patients, healthcare providers, and researchers all contribute to generating valuable data, and ensuring that data is shared transparently while acknowledging contributors' roles is a challenge[39].

## **Potential for Genetic Discrimination**

The wealth of genetic information obtained through personalized medicine could lead to genetic discrimination by insurers, employers, or even within the healthcare system itself. Ethical considerations should address how to prevent such discrimination and protect individuals from potential biases based on their genetic profiles[39].

## **Long-Term Implications and Autonomy**

Personalized medicine may present long-term implications, especially as new treatments and interventions emerge. Ethical discussions should encompass considerations of how decisions made today might affect a patient's future health and well-being. Preserving patient autonomy in treatment choices and data sharing is essential. As personalized medicine expands its horizons, grappling with these ethical considerations is pivotal. Balancing innovation with patient rights, transparency with data security, and societal benefits with individual consent requires collaborative efforts from healthcare professionals, researchers, policymakers, and society at large. By navigating these ethical challenges, we can ensure that the transformational potential of personalized medicine is harnessed responsibly and ethically[40].

# CONCLUSION

This chapter has delved into the forefront of healthcare innovation, showcasing how cutting-edge analytical methods are revolutionizing patient care. This exploration underscores the significant shift from a traditional one-size-fits-all approach to a future where healthcare is tailored to the unique genetic, molecular, and clinical characteristics of each individual. The integration of wearable sensors and point-of-care diagnostics has been revealed as a game-changer, allowing patients and healthcare providers to actively engage in managing health. Meanwhile, bioinformatics and data integration have emerged as indispensable allies, facilitating the translation of complex biological data into actionable insights. As we march forward into a new era of healthcare, ethical considerations are essential guideposts. The protection of patient privacy, ensuring equitable access to benefits, and addressing the consequences of genetic information are moral imperatives that must be addressed hand in hand with technological advancements.

##### REFERENCES

[1] I. S. Chan and G. S. Ginsburg, “Personalized medicine: progress and promise,” *Annual review of genomics and human genetics*, vol. 12, pp. 217–244, 2011, doi: 10.1146/annurev-genom-082410-101446.

[2] K. K. Jain, “Personalized medicine.,” *Current opinion in molecular therapeutics*, vol. 4, no. 6, pp. 548–558, 2002.

[3] S. Mura and P. Couvreur, “Nanotheranostics for personalized medicine,” *Advanced drug delivery reviews*, vol. 64, no. 13, pp. 1394–1416, 2012, doi: 10.1016/j.addr.2012.06.006.

[4] P. C. Ng, S. S. Murray, S. Levy, and J. C. Venter, “An agenda for personalized medicine,” *Nature*, vol. 461, no. 7265, pp. 724–726, 2009, doi: 10.1038/461724a.

[5] C. D. Collins *et al.*, “The application of genomic and proteomic technologies in predictive, preventive and personalized medicine,” *Vascular pharmacology*, vol. 45, no. 5, pp. 258–267, 2006, doi: 10.1016/j.vph.2006.08.003.

[6] K. K. Jain, “Role of pharmacoproteomics in the development of personalized medicine,” *Pharmacogenomics*, vol. 5, no. 3, pp. 331–336, 2004, doi: 10.1517/phgs.5.3.331.29830.

[7] M. Ouzounian, D. S. Lee, A. O. Gramolini, A. Emili, M. Fukuoka, and P. P. Liu, “Predict, prevent and personalize: Genomic and proteomic approaches to cardiovascular medicine,” *Canadian Journal of Cardiology*, vol. 23, pp. 28A-33A, 2007, doi: 10.1016/S0828-282X(07)71003-6.

[8] M. Su, Z. Zhang, L. Zhou, C. Han, C. Huang, and E. C. Nice, “Proteomics, personalized medicine and cancer,” *Cancers*, vol. 13, no. 11, p. 2512, 2021, doi: 10.3390/cancers13112512.

[9] M. Verma, “Personalized medicine and cancer,” *Journal of personalized medicine*, vol. 2, no. 1, pp. 1–14, 2012, doi: 10.3390/jpm2010001.

[10] T. P. Aneesh, S. Sekhar, A. Jose, L. Chandran, and S. M. Zachariah, “Pharmacogenomics: the right drug to the right person,” *Journal of clinical medicine research*, vol. 1, no. 4, p. 191, 2009.

[11] R. Cacabelos, “Pharmacogenomics, nutrigenomics and therapeutic optimization in Alzheimer’s disease,” 2005, doi: 10.2217/1745509X.1.2.303.

[12] R. Cacabelos, “Pharmacogenomics of drugs used to treat brain disorders,” *Expert Review of Precision Medicine and Drug Development*, vol. 5, no. 3, pp. 181–234, 2020, doi: 10.1080/23808993.2020.1738217.

[13] W. E. Evans and M. V. Relling, “Moving towards individualized medicine with pharmacogenomics,” *Nature*, vol. 429, no. 6990, pp. 464–468, 2004, doi: 10.1038/nature02626.

[14] Y. Guo, S. Shafer, P. Weller, J. Usuka, and G. Peltz, “Pharmacogenomics and drug development,” 2005, doi: 10.2217/14622416.6.8.857.

[15] N. Cullin, C. A. Antunes, R. Straussman, C. K. Stein-Thoeringer, and E. Elinav, “Microbiome and cancer,” *Cancer Cell*, vol. 39, no. 10, pp. 1317–1341, 2021, doi: 10.1016/j.ccell.2021.08.006.

[16] B. A. Helmink, M. W. Khan, A. Hermann, V. Gopalakrishnan, and J. A. Wargo, “The microbiome, cancer, and cancer therapy,” *Nature medicine*, vol. 25, no. 3, pp. 377–388, 2019, doi: 10.1038/s41591-019-0377-7.

[17] S. Khanna *et al.*, “Gut microbiome predictors of treatment response and recurrence in primary Clostridium difficile infection,” *Alimentary pharmacology & therapeutics*, vol. 44, no. 7, pp. 715–727, 2016, doi: 10.1111/apt.13750.

[18] N. C. Knox, J. D. Forbes, G. Van Domselaar, and C. N. Bernstein, “The gut microbiome as a target for IBD treatment: are we there yet?,” *Current treatment options in gastroenterology*, vol. 17, pp. 115–126, 2019, doi: 10.1007/s11938-019-00221-w.

[19] J. L. McQuade, C. R. Daniel, B. A. Helmink, and J. A. Wargo, “Modulating the microbiome to improve therapeutic response in cancer,” *The Lancet Oncology*, vol. 20, no. 2, pp. e77–e91, 2019, doi: 10.1016/S1470-2045(18)30952-5.

[20] D. A. Schupack, R. A. Mars, D. H. Voelker, J. P. Abeykoon, and P. C. Kashyap, “The promise of the gut microbiome as part of individualized treatment strategies,” *Nature Reviews Gastroenterology & Hepatology*, vol. 19, no. 1, pp. 7–25, 2022, doi: 10.1038/s41575-021-00499-1.

[21] M. V. Seeman, “The gut microbiome and antipsychotic treatment response,” *Behavioural Brain Research*, vol. 396, p. 112886, 2021, doi: 10.1016/j.bbr.2020.112886.

[22] S. K. Kang, A. Fagerlin, and R. S. Braithwaite, “A roadmap for personalized care in radiology,” *Radiology*, vol. 277, no. 3, pp. 638–643, 2015, doi: 10.1148/radiol.2015151187.

[23] M. F. Kircher, H. Hricak, and S. M. Larson, “Molecular imaging for personalized cancer care,” *Molecular oncology*, vol. 6, no. 2, pp. 182–195, 2012, doi: 10.1016/j.molonc.2012.02.005.

[24] P. Lambin *et al.*, “Radiomics: the bridge between medical imaging and personalized medicine,” *Nature reviews Clinical oncology*, vol. 14, no. 12, pp. 749–762, 2017, doi: 10.1038/nrclinonc.2017.141.

[25] F. A. McAlister, A. Laupacis, and P. W. Armstrong, “Finding the right balance between precision medicine and personalized care,” *Cmaj*, vol. 189, no. 33, pp. E1065–E1068, 2017, doi: 10.1503/cmaj.170107.

[26] X. Wang and X. J. Zhou, “Magnetic resonance imaging in personalized medicine,” *Science China Life Sciences*, vol. 60. Springer, pp. 1–4, 2017.

[27] V. Gubala, L. F. Harris, A. J. Ricco, M. X. Tan, and D. E. Williams, “Point of care diagnostics: status and future,” *Analytical chemistry*, vol. 84, no. 2, pp. 487–515, 2012, doi: 10.1021/ac2030199.

[28] S. Nayak, N. R. Blumenfeld, T. Laksanasopin, and S. K. Sia, “Point-of-care diagnostics: recent developments in a connected age,” *Analytical chemistry*, vol. 89, no. 1, pp. 102–123, 2017, doi: 10.1021/acs.analchem.6b04630.

[29] S. K. Vashist, “Point-of-care diagnostics: Recent advances and trends,” *Biosensors*, vol. 7, no. 4, p. 62, 2017, doi: 10.3390/bios7040062.

[30] P. Yager, G. J. Domingo, and J. Gerdes, “Point-of-care diagnostics for global health,” *Annu. Rev. Biomed. Eng.*, vol. 10, pp. 107–144, 2008, doi: 10.1146/annurev.bioeng.10.061807.160524.

[31] C. Chen, H. Huang, and C. H. Wu, “Protein Bioinformatics Databases and Resources,” *Methods Mol Biol*, vol. 1558, pp. 3–39, 2017, doi: 10.1007/978-1-4939-6783-4\_1.

[32] H. Huang, Z.-Z. Hu, C. N. Arighi, and C. H. Wu, “Integration of bioinformatics resources for functional analysis of gene expression and proteomic data,” *Front Biosci*, vol. 12, pp. 5071–5088, Sep. 2007, doi: 10.2741/2449.

[33] A. Kremer, R. Schneider, and G. C. Terstappen, “A bioinformatics perspective on proteomics: data storage, analysis, and integration,” *Biosci Rep*, vol. 25, no. 1–2, pp. 95–106, 2005, doi: 10.1007/s10540-005-2850-4.

[34] G. Liu and S. Neelamegham, “Integration of systems glycobiology with bioinformatics toolboxes, glycoinformatics resources, and glycoproteomics data,” *Wiley Interdiscip Rev Syst Biol Med*, vol. 7, no. 4, pp. 163–181, 2015, doi: 10.1002/wsbm.1296.

[35] F. Rohart, B. Gautier, A. Singh, and K.-A. Lê Cao, “mixOmics: An R package for ’omics feature selection and multiple data integration,” *PLoS Comput Biol*, vol. 13, no. 11, p. e1005752, Nov. 2017, doi: 10.1371/journal.pcbi.1005752.

[36] M. A. Wörheide, J. Krumsiek, G. Kastenmüller, and M. Arnold, “Multi-omics integration in biomedical research - A metabolomics-centric review,” *Anal Chim Acta*, vol. 1141, pp. 144–162, Jan. 2021, doi: 10.1016/j.aca.2020.10.038.

[37] K. Inamura, “Ethical Considerations about Genomic Medicine Implementation: Lessons Learned from the eMERGE III Study,” *J Pers Med*, vol. 10, no. 4, p. 195, Oct. 2020, doi: 10.3390/jpm10040195.

[38] Y. Joly, K. M. Saulnier, G. Osien, and B. M. Knoppers, “The ethical framing of personalized medicine,” *Curr Opin Allergy Clin Immunol*, vol. 14, no. 5, pp. 404–408, Oct. 2014, doi: 10.1097/ACI.0000000000000091.

[39] P. Salari and B. Larijani, “Ethical Issues Surrounding Personalized Medicine: A Literature Review,” *Acta Med Iran*, vol. 55, no. 3, pp. 209–217, Mar. 2017.

[40] J. Zhou, L. Sun, L. Chen, S. Liu, L. Zhong, and M. Cui, “Comprehensive metabolomic and proteomic analyses reveal candidate biomarkers and related metabolic networks in atrial fibrillation,” *Metabolomics*, vol. 15, pp. 1–13, 2019, doi: 10.1007/s11306-019-1557-7.